We previously demonstrated that targeting the Golgi apparatus using an Arf1 inhibitor, M-COPA, exerted a selective antitumor effect on gastric cancers amplifying the RTK genes MET and FGFR2 by downregulating the cell surface expression of such RTKs [33]. The gene discussed is ARF1; the disease is gastric cancer.